Tyra Bioscience (TYRA)
NASDAQ:TYRA
Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$35.56
-$0.12(-0.75%)
At close: 4:00 PM EST
$35.56
-$0.12(-0.75%)
Day’s Range― - ―
52-Week Range$8.98 - $40.65
Previous CloseN/A
Volume80.11K
Average Volume (3M)370.94K
Market Cap
$1.68B
Enterprise Value$1.65B
Total Cash (Recent Filing)$383.47M
Total Debt (Recent Filing)$5.70M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 06, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding59,470,383
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.95K
Enterprise Value/Ebitda-12.63
Forecast
1Y Price Target
$50.90Price Target Upside43.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low debt and a sizable equity cushion reduce solvency risk for a clinical-stage biotech. This balance-sheet strength gives management financial flexibility to fund R&D, negotiate partnerships, and survive longer development timelines without distress-driven fire sales.
Recent $126M Equity FinancingA sizable equity raise materially extends near-term runway, lowering the immediacy of fundraising risk. That structural liquidity enables the company to progress clinical programs and reach value-creating milestones that can attract partnerships or non-dilutive funding.
Proprietary SNÅP Platform & FGFR FocusA platform-driven approach focused on FGFR resistance biology creates a repeatable discovery engine and differentiated IP. If the SNÅP platform consistently yields clinically actionable candidates, it supports durable competitive advantage and multiple program value creation over time.
Bears Say
Pre-revenue With Widening LossesPersistently widening operating losses without product revenue mean the company will remain dependent on external capital until approvals or partnerships materialize. This structural loss profile increases dilution risk and lengthens the path to sustainable profitability.
High And Rising Cash BurnConsistent negative operating and free cash flow at six-figure monthly rates makes financing a recurring structural need. High burn reduces optionality for program prioritization and forces either frequent capital raises or trade-offs in R&D pacing, hindering long-term strategic flexibility.
Dependence On External Financing / Dilution RiskBecause operations are funded primarily via equity and occasional collaborations, the company faces recurring dilution risk. Structural reliance on capital markets or partners can impair returns to existing shareholders and influence program decisions toward near-term financeability over optimal science.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $8.98 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.68B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Aug 06, 2026 which is in 48 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on May 13, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.588 by -$0.052.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.65.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 59,470,383 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.588. Following the earnings report the stock price went up 3.785%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.90 (43.14% Upside)
$50.90 (43.14% Upside)
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $528.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
-42.66%
Trailing 12-Months
Asset Growth
19.96%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$50.90
▲(43.14% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Gossamer Bio
―
Nurix Therapeutics
―
―
Ownership Overview
29.85% Insiders
4.35% Mutual Funds
10.87% Other Institutional Investors
48.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---